Loading…
← CockpitCompetitor Analysis › 096530.KS Seegene, Inc.Open in the cockpit ↗

Seegene, Inc.096530.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Medical Specialties
Momentum weak 34
Mkt cap
$808M
US dollars, full cap
Free float
53%
of shares outstanding
$/day
$6.50M
20-day average traded
Fwd P/E
20.0×
forward earnings
ROIC−WACC
+2.3 pp
WACC 6.5%
Hurdle
+9 pp
Req g minus delivered
Next earnings
92 days
18 Feb 2027
Close · KRW₩23,700
1D-1.0%
1W-5.0%
1M-35.8%
3M-26.3%
6M-25.9%
YTD-0.4%
1Y-9.4%
ATR %6.8%
52w lowhigh41.4% off high

What Seegene does

Employees: 822

Seegene at a glance

Size Seegene (096530.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $808M, the 272nd largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩23,700 on 18 Nov 2026.

Performance Over six months the shares fell 25.9%, against -12.6% for the median peer and -37.2% for the South Korea market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 13.1% over the last twelve months (peer median +7.3%); the operating margin is 13.1% (peer median 10.2%).

Valuation It trades at 20.0× forward earnings against a peer median of 19.9× (7th most expensive of 14).

Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is -16%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.3 points above its cost of capital (6.5% WACC).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 88096530.KS 76
Six months, rebased to 100: Seegene against the median of its 20 peers (local-currency closes).

Seegene financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩519B₩474B₩414B₩367B₩854B
Revenue growth—+14%+13%-57%—
Gross profit₩313B₩271B₩205B₩180B₩466B
EBITDA₩133B₩105B₩54.7B₩35.7B₩239B
Net income₩46.8B₩48.3B-₩8.76B₩669M₩182B
Free cash flow₩95.5B₩112B₩45.4B₩69.8B₩256B
Capital expenditure₩72.0B₩40.5B₩43.6B₩31.9B₩72.5B
Total debt₩124B₩130B₩144B₩142B₩159B

Quarterly statements and history in the cockpit →

Seegene competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%AMSMCAP688068688805KIDSSETL1187BBNXMLABCTKB60336736001302VREX2190301602688656002658688108096530.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Seegene is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×AMSMCAP1187MLAB60336736002190688656300463002658688108096530.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Seegene is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%AMSMCAP6888051187MLAB60336736002190301602688656300463002658096530.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Seegene is the large dot.

Seegene competitors and peer comparison

How Seegene compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Seegene against its 20 peers (data as of 18 Nov 2026)
Measure096530.KSPeer medianRank in peer set
1-month return-35.8%-4.8%lowest of 21
6-month return-25.9%-12.6%7th lowest of 21
Distance from 52-week high-41.4%-37.6%9th lowest of 21
Revenue growth (TTM)+13.1%+7.3%9th highest of 21
Operating margin13.1%10.2%8th highest of 21
Forward P/E20.0×19.9×7th most expensive of 14
Growth the price implies (Req g, 7 yrs)-6.7%10.4%3rd least demanding of 15
Growth delivered (Del g)-15.9%+11.8%lowest of 15
Hurdle (Req g minus delivered)+9.2 pp+2.6 pp6th most demanding of 15
ROIC minus cost of capital+2.3 pp-1.3 pp7th highest of 21
EV / EBITDA4.9×14.7×cheapest of 9
Net debt / EBITDA-3.2×0.3×3rd least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Seegene 096530.KSSouth Korea$808M-26%+13%13%20.0×-6.7%-15.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%20.7×20.0%+21.4%
MedCap MCAP.STSweden$811M-4%+17%15%25.8×2.7%+20.9%
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%n/an/an/a
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%n/a35.6%+17.1%
OrthoPediatrics KIDSUnited States$826M+71%+16%-8%n/an/an/a
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%n/an/an/a
Cofoe Medical Technology 1187.HKHong Kong$836M-11%+40%10%13.1×-6.4%+6.6%
Beta Bionics BBNXUnited States$779M+42%+44%-73%n/an/an/a
Mesa Laboratories MLABUnited States$775M+33%+2%10%11.5×21.3%+13.2%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%n/an/an/a
Cisen Pharmaceutical 603367.SSChina$843M-15%-6%8%7.9×-14.6%-1.3%
Modern Dental 3600.HKHong Kong$844M+24%+12%22%8.5×-7.1%+11.3%
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%19.8×9.6%+15.5%
Varex Imaging VREXUnited States$771M+79%+5%8%19.9×n/an/a
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%14.4×3.8%+105.8%
Shantou Institute of Ultrasonic Instruments 301602.SZChina$858M-25%+4%30%n/a11.1%+4.6%
HOB Biotech 688656.SSChina$858M-33%+6%7%166.9×37.6%+12.4%
Maccura Biotechnology 300463.SZChina$756M-18%-1%-4%421.0×7.9%-10.2%
Beijing SDL Technology 002658.SZChina$864M-34%-13%9%22.4×16.8%+2.9%
Sino Medical Sciences Technology 688108.SSChina$753M-41%+22%19%60.0×27.9%+9.9%

Questions

Which companies are Seegene's closest peers?
The cockpit's peer set: Advanced Medical Solutions (AMS.L), MedCap (MCAP.ST), Beijing Hotgen Biotech (688068.SS), Ningbo Jansen Superconducting Technologies (688805.SS), OrthoPediatrics (KIDS), Standard Engineering Technology (SETL.NS), Cofoe Medical Technology (1187.HK), Beta Bionics (BBNX).
Is Seegene expensive compared with its peers?
On forward p/e it trades at 20.0× against a peer median of 19.9×, 7th most expensive of 14 in its peer set. For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is -16%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Seegene stock performed?
Over six months to 18 Nov 2026 the shares returned -25.9% against -12.6% for the median peer; over one year -9.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.